Does Wegovy Start Working Right Away, or Does It Take Time?

What is actually happening in your body on that first injection?

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases naturally after eating; it signals to the brain that you are full, slows the rate at which your stomach empties, and influences insulin release. Wegovy mimics that signal continuously rather than only at mealtimes.

After a single subcutaneous injection, semaglutide is absorbed gradually from the tissue under the skin, reaching peak blood concentration roughly 24 to 72 hours later. Because the molecule is engineered to resist breakdown, it stays active for around a week, which is why one injection per week is sufficient. But a single dose at the 0.25mg starting level does not flood the system. It is a deliberately low amount chosen to let your body adjust, not to produce immediate weight loss. The clinical profile of semaglutide makes clear that tolerability at this early stage matters as much as efficacy.

Think of the pen tucked into the fridge door: it will be there every week, and that consistency is the point. The mechanism is cumulative. Blood levels rise a little more after each weekly dose until, at around four to five weeks, the drug approaches what pharmacologists call steady state, a stable plateau where the amount entering the body each week roughly equals the amount cleared. Only from that point does the full appetite-suppressing effect begin to exert itself consistently. The Wegovy overview on our site covers the broader picture if you want the context alongside the timeline.

When do most people actually start feeling a difference?

The honest answer is: it varies, and the variation is wide. Some people report a noticeable drop in appetite within the first one to two weeks at 0.25mg, meals feel satisfying on less food, snack cravings quieten. Others feel very little until the dose increases for the first time at week five, when the effect sharpens.

Gastrointestinal side effects (nausea, loose stools, indigestion) are often the first sign the drug is active. They are not the goal, but their presence does confirm semaglutide is doing something. According to NHS guidance on semaglutide, these effects tend to ease as the body adjusts, typically within a few weeks of each dose step. Pushing through them, rather than abandoning treatment, is usually the right call, though your prescriber should know if they are severe.

Weight on the scales is a slower story. Water retention, the weight of food in transit, daily fluctuation: the scales are noisy. Most people see a measurable downward trend from around week four to eight. The clearest trajectory becomes apparent once the maintenance dose is reached and sustained, which for most people is several months into treatment. If you want to read more about the earliest phase of treatment in detail, that page goes deeper on weeks one to four specifically.

What do the clinical trial results actually show about timing?

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults over 68 weeks on semaglutide 2.4mg. Average weight loss across the whole group was around 15% of starting body weight. That figure came from 68 weeks of sustained treatment, not a few injections.

Importantly, the trial tracked weight at intervals throughout. Weight loss in the early weeks was modest. The curve steepened noticeably once participants were on higher maintenance doses. The greatest reductions came in the middle phase of the trial, after months of consistent weekly dosing.

The MHRA-approved titration schedule (0.25mg, 0.5mg, 1.0mg, 1.7mg, building toward 2.4mg) is not bureaucracy. Each step gives the body time to adapt and allows appetite suppression to deepen without overwhelming the gut. Rushing the schedule does not produce faster results; it produces more side effects and early discontinuation. For a fuller look at what drives results across the treatment period, the evidence is more encouraging once you understand the timeline properly.

Does starting slowly mean something is going wrong?

Not at all. A slow start is the design, not a fault. Patients sometimes worry that nothing is happening in the first few weeks, or that the drug is not working for them personally. In most cases the process is simply unfolding as intended.

A few things genuinely are worth raising with your prescriber: side effects that are not easing after two to three weeks at a given dose; no appetite change whatsoever after reaching the 1.0mg dose; or weight that is moving sharply in the wrong direction. These are not catastrophic signals, but they are worth a conversation rather than silent perseverance.

What is not worth acting on: impatience in week two at 0.25mg. The medicine is working. The scale just has not caught up yet. Wegovy is a prescription medicine and the clinical review process exists partly for this reason, a prescriber can distinguish a normal slow start from a genuine non-response. You can explore how to access Wegovy through a regulated UK pharmacy and understand what that clinical oversight involves before you begin. Our weight-loss treatment information sets out the broader options, including how semaglutide fits alongside lifestyle changes, because the drug works best when it is not doing the job entirely alone.